Archford Capital Strategies’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-8,030
| Closed | -$602K | – | 263 |
|
|
2023
Q3 | $602K | Buy |
8,030
+112
| +1% | +$8.62K | 0.12% | 173 |
|
|
2023
Q2 | $615K | Sell |
7,918
-244
| -3% | -$19.5K | 0.12% | 183 |
|
|
2023
Q1 | $683K | Buy |
8,162
+145
| +2% | +$12K | 0.14% | 164 |
|
|
2022
Q4 | $688K | Buy |
8,017
+670
| +9% | +$53.1K | 0.16% | 154 |
|
|
2022
Q3 | $453K | Buy |
7,347
+183
| +3% | +$11.5K | 0.12% | 189 |
|
|
2022
Q2 | $443K | Buy |
7,164
+1,975
| +38% | +$122K | 0.11% | 192 |
|
|
2022
Q1 | $310K | Buy |
5,189
+294
| +6% | +$18.8K | 0.07% | 234 |
|
|
2021
Q4 | $355K | Buy |
4,895
+223
| +5% | +$15.4K | 0.08% | 227 |
|
|
2021
Q3 | $326K | Buy |
4,672
+292
| +7% | +$20.5K | 0.08% | 238 |
|
|
2021
Q2 | $302K | Buy |
4,380
+429
| +11% | +$28.6K | 0.08% | 236 |
|
|
2021
Q1 | $260K | Sell |
3,951
-6,671
| -63% | -$430K | 0.07% | 239 |
|
|
2020
Q4 | $670K | Buy |
10,622
+272
| +3% | +$16.4K | 0.15% | 167 |
|
|
2020
Q3 | $654K | Buy |
10,350
+438
| +4% | +$30.4K | 0.18% | 150 |
|
|
2020
Q2 | $763K | Buy |
9,912
+149
| +2% | +$11.4K | 0.23% | 132 |
|
|
2020
Q1 | $730K | Buy |
+9,763
| New | +$675K | 0.29% | 116 |
|
|
2019
Q3 | – | Sell |
-1,300
| Closed | -$88K | – | 332 |
|
|
2019
Q2 | $88K | Hold |
1,300
| – | – | 0.03% | 246 |
|
|
2019
Q1 | $85K | Hold |
1,300
| – | – | 0.03% | 249 |
|
|
2018
Q4 | $81K | Sell |
1,300
-175
| -12% | -$12.2K | 0.03% | 240 |
|
|
2018
Q3 | $114K | Hold |
1,475
| – | – | 0.04% | 238 |
|
|
2018
Q2 | $104K | Hold |
1,475
| – | – | 0.04% | 250 |
|
|
2018
Q1 | $106K | Buy |
+1,475
| New | +$117K | 0.04% | 166 |
|
|
2017
Q4 | – | Sell |
-4,125
| Closed | -$334K | – | 191 |
|
|
2017
Q3 | $334K | Buy |
+4,125
| New | +$315K | 0.13% | 164 |
|
|
2017
Q2 | – | Sell |
-292
| Closed | -$20K | – | 350 |
|
|
2017
Q1 | $20K | Sell |
292
-238
| -45% | -$16.7K | 0.01% | 370 |
|
|
2016
Q4 | $37K | Sell |
530
-1,845
| -78% | -$137K | 0.02% | 277 |
|
|
2016
Q3 | $187K | Buy |
2,375
+2,246
| +1,741% | +$182K | 0.08% | 181 |
|
|
2016
Q2 | $11K | Buy |
+129
| New | +$11.4K | 0.01% | 379 |
|
|
2016
Q1 | – | Sell |
-312
| Closed | -$32K | – | 334 |
|
|
2015
Q4 | $32K | Hold |
312
| – | – | 0.01% | 313 |
|
|
2015
Q3 | $31K | Buy |
312
+14
| +5% | +$1.55K | 0.02% | 226 |
|
|
2015
Q2 | $35K | Sell |
298
-28
| -9% | -$3.06K | 0.03% | 222 |
|
|
2015
Q1 | $32K | Sell |
326
-67
| -17% | -$6.8K | 0.02% | 236 |
|
|
2014
Q4 | $37K | Sell |
393
-270
| -41% | -$27.9K | 0.03% | 235 |
|
|
2014
Q3 | $70K | Sell |
663
-83
| -11% | -$8.13K | 0.06% | 176 |
|
|
2014
Q2 | $61.9K | Sell |
746
-28
| -4% | -$2.18K | 0.05% | 197 |
|
|
2014
Q1 | $54.8K | Buy |
+774
| New | +$60.7K | 0.05% | 208 |
|
Other funds holding GILD
Archford Capital Strategies's GILD Position: Q4 2023 in Review
Archford Capital Strategies sold out of Gilead Sciences (GILD) in Q4 2023, closing a stake of 8,030 shares — an estimated $602K sold.
Archford Capital Strategies first reported a position in GILD in Q1 2014 and held it in 34 quarters. The position peaked at $763K in Q2 2020. 1,776 funds tracked by Wall St. Rank hold GILD as of Q4 2023.
- Archford Capital Strategies reported no remaining Gilead Sciences position as of Q4 2023 after selling out during the quarter.
- Archford Capital Strategies sold 8,030 Gilead Sciences shares in Q4 2023, an estimated $602K.
- Archford Capital Strategies first reported a position in Gilead Sciences in Q1 2014 and held it in 34 quarters.
- Archford Capital Strategies's Gilead Sciences position peaked at $763K in Q2 2020.
- 1,776 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2023.
Based on Archford Capital Strategies's 13F filing for Q4 2023, filed 12 Jan 2024.